These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14726401)

  • 1. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
    Kvasnicka HM; Thiele J; Staib P; Schmitt-Graeff A; Griesshammer M; Klose J; Engels K; Kriener S
    Blood; 2004 May; 103(9):3549-51. PubMed ID: 14726401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
    Kvasnicka HM; Thiele J; Staib P; Engels K; Kriener S; Schmitt-Graeff A
    Pathologe; 2004 Mar; 25(2):127-34. PubMed ID: 15010998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K; Round A; Stein K; Garside R; Price A
    Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
    Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
    Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
    Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y; Wahner AE; Nguyen PL
    Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
    Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib therapy in chronic myeloid leukemia].
    Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
    Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
    Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
    Angstreich GR; Smith BD; Jones RJ
    Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
    Kantarjian HM; Cortes JE; O'Brien S; Luthra R; Giles F; Verstovsek S; Faderl S; Thomas D; Garcia-Manero G; Rios MB; Shan J; Jones D; Talpaz M
    Blood; 2004 Oct; 104(7):1979-88. PubMed ID: 15198956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
    Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
    Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.